A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis

NCT07675954 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

294

Enrollment

OTHER

Sponsor class

Conditions

Rifampicin-Resistant Tuberculosis

Interventions

DRUG: MDR-END Plus regimen
DRUG: Standard-of-care (SoC) treatment

Sponsor

Seoul National University Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]